Guggenheim Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics (NASDAQ:TVTX) had its price objective hoisted by equities researchers at Guggenheim from $49.00 to $54.00 in a research report issued on Tuesday, MarketBeat reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 31.87% from the company’s previous close.

Several other analysts have also recently commented on TVTX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut shares of Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. JPMorgan Chase & Co. decreased their price target on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 25th. Piper Sandler boosted their price target on shares of Travere Therapeutics from $35.00 to $38.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $47.00 price target on shares of Travere Therapeutics in a research note on Tuesday. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $42.50.

Travere Therapeutics Stock Down 2.8%

Shares of TVTX stock opened at $40.95 on Tuesday. The stock has a market cap of $3.78 billion, a P/E ratio of -136.50 and a beta of 0.86. Travere Therapeutics has a 52 week low of $13.88 and a 52 week high of $43.31. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71. The company’s fifty day simple moving average is $29.57 and its two-hundred day simple moving average is $31.37.

Insider Activity

In other news, CFO Christopher R. Cline sold 1,014 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $42.61, for a total transaction of $43,206.54. Following the sale, the chief financial officer directly owned 116,899 shares in the company, valued at approximately $4,981,066.39. This represents a 0.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roy D. Baynes sold 10,000 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $33.00, for a total transaction of $330,000.00. Following the sale, the director owned 37,500 shares in the company, valued at $1,237,500. This represents a 21.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 444,127 shares of company stock worth $15,206,744. 4.19% of the stock is owned by insiders.

Institutional Trading of Travere Therapeutics

Several hedge funds have recently made changes to their positions in TVTX. State of Wyoming bought a new position in Travere Therapeutics during the 4th quarter valued at about $37,000. Torren Management LLC bought a new position in Travere Therapeutics during the 4th quarter valued at about $38,000. Comerica Bank grew its holdings in Travere Therapeutics by 77.5% during the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after purchasing an additional 492 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in Travere Therapeutics by 69.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock valued at $45,000 after purchasing an additional 487 shares during the last quarter. Finally, First Horizon Corp bought a new position in Travere Therapeutics during the 3rd quarter valued at about $36,000.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s rare kidney-disease franchise, adding an estimated ~30,000 patients to the U.S. addressable market and supporting multi-year revenue/earnings upside. Article Title
• Positive Sentiment: Market reacted strongly to the approval — shares jumped about ~37% on the news as investors priced in first-mover status, premium pricing potential and material volume-driven revenue growth for Filspari. Article Title
• Positive Sentiment: Multiple brokerages raised ratings/price targets following the approval (examples: Canaccord to $56, Guggenheim to $54, Piper Sandler to $49 overweight, Wedbush to $44, HC Wainwright reaffirmed buy). These upgrades signal increased analyst confidence in TAM expansion and revenue trajectory. Article Title
• Neutral Sentiment: Guggenheim issued a positive forecast note on TVTX that accompanies their price-target lift; this is incremental institutional support but not a guarantee of sustained momentum. Article Title
• Neutral Sentiment: Unusually high options activity and elevated trading volume were reported around the approval-related move, indicating heightened short-term speculation and positioning that can amplify volatility. Article Title
• Neutral Sentiment: Company-hosted commentary/transcripts and mainstream coverage (Seeking Alpha slides/transcript, MSN health reports) are providing more detail on label scope and commercial plans; useful for modeling uptake but not yet concrete sales figures. Article Title
• Negative Sentiment: Some analysts caution that recent earnings-estimate revision trends may limit further near-term upside despite the approval; elevated expectations and heavy short-term speculative flows raise the risk of a pullback or consolidation. Article Title

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.